- Home
- ALEC
ALEC
Alector Inc.
as 11-21-2024 10:30am EST
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 454.5M | IPO Year: | 2019 |
| Target Price: | $17.75 | AVG Volume (30 days): | 722.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.60 - $8.90 | Next Earning Date: | 11-06-2024 |
| Revenue: | $61,508,000 | Revenue Growth: | -36.14% |
| Revenue Growth (this year): | -34.08% | Revenue Growth (next year): | 118.87% |
Stock Insider Trading Activity of Alector Inc. (ALEC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | ALEC | Chief Executive Officer | Sep 3 '24 | Sell | $4.88 | 26,499 | $129,386.67 | 1,948,746 | |
| Romano Gary | ALEC | Chief Medical Officer | Sep 3 '24 | Sell | $4.88 | 8,478 | $41,385.36 | 179,795 | |
| GRASSO MARC | ALEC | Chief Financial Officer | Sep 3 '24 | Sell | $4.88 | 7,297 | $35,620.31 | 130,740 | |
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Sep 3 '24 | Sell | $4.88 | 13,926 | $67,981.16 | 291,715 |
Latest Alector Inc. News
ALEC Breaking Stock News: Dive into ALEC Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Alector Gets Credit Facility for Up to $50 Million From Hercules Capital
GlobeNewswire
7 days ago
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
Zacks
15 days ago
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
15 days ago
Alector: Q3 Earnings Snapshot
GlobeNewswire
15 days ago
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
20 days ago
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
Simply Wall St.
22 days ago
Is Alector (NASDAQ:ALEC) In A Good Position To Deliver On Growth Plans?
MT Newswires
2 months ago
Alector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia
Compare ALEC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALEC Alector Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.